Annals of internal medicine
-
Comment Randomized Controlled Trial Multicenter Study
In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo.
Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. 38364841.
-
Comment Randomized Controlled Trial
In adults with COVID-19 and severe hypoxemia, lower vs. higher oxygenation targets increased days alive without life support.
Nielsen FM, Klitgaard TL, Siegemund M, et al; HOT-COVID Trial Group. Lower vs higher oxygenation target and days alive without life support in COVID-19: the HOT-COVID randomized clinical trial. JAMA. 2024;331:1185-1194. 38501214.
-
Comment Randomized Controlled Trial
In adults with AMI who are at risk for HF, empagliflozin did not reduce a composite of first HF hospitalization or all-cause death at 18 mo.